Scientists hope that a new approach to vaccine development, combined with improved surveillance of potential future threats of outbreak, could help to massively reduce the impact of deadly diseases such as Ebola, Marburg and Lassa fever.
The University of Cambridge has signed an agreement with one of China’s largest universities to encourage innovation and entrepreneurship in one of China’s fastest-growing high-tech clusters.
Five leading universities, including the University of Cambridge, have formed a partnership to develop and commercialise agritech research, in order to improve sustainability, increase productivity and contribute to global food security.
The new joint centre will support innovative research into smart cities and fully integrated urban environments.
Researchers from the UK and Denmark have developed a new method to predict the physical stability of drug candidates, which could help with the development of new and more effective medicines for patients. The technology has been licensed to Cambridge spin-out company TeraView, who are developing it for use in the pharmaceutical industry in order to make medicines that are more easily released in the body.
Andy Neely is Cambridge’s Pro-Vice-Chancellor for Enterprise and Business Relations, a role which oversees the University’s activities in innovation, commercialisation and entrepreneurship. After six months in the role, he sees an entrepreneurial ecosystem that may appear complex at first – but a deeper examination reveals a combination of knowledge, expertise, support and infrastructure that makes Cambridge one of the most enterprising and entrepreneurial cities in the world.
Researchers have successfully incorporated washable, stretchable and breathable electronic circuits into fabric, opening up new possibilities for smart textiles and wearable electronics. The circuits were made with cheap, safe and environmentally friendly inks, and printed using conventional inkjet printing techniques.
The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.
Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.
Improbable, founded by Cambridge alumni Herman Narula (Girton 2007) and Rob Whitehead (Robinson 2009), became the UK's latest $1billion tech startup this week.